BPC-157 / TB-500

The two peptides act on complementary axes in tissue-repair research models. BPC-157 has been characterized as an angiogenic and growth-factor-modulating peptide (VEGFR2 and Akt-eNOS-NO signaling), while TB-500 acts intracellularly by sequestering G-actin and supporting cell migration. Researchers studying tendon, dermal, and cardiovascular injury models often combine the two to investigate whether vascularization and cytoskeletal remodeling produce additive or synergistic effects in vitro and in animal models. Neither peptide is FDA-approved for human use.

BPC-157 is a 15-amino-acid partial sequence of human gastric Body Protection Compound. Preclinical work by Sikiric and colleagues correlates its angiogenic activity with upregulated VEGFR2 expression, nitric oxide release, FAK-paxillin signaling, and modulation of growth-factor pathways. TB-500 represents the actin-binding heptapeptide (Ac-LKKTETQ) from Thymosin β4, a 43-aa intracellular protein that sequesters G-actin, regulates the G/F-actin equilibrium, and supports endothelial / fibroblast migration. Both peptides exhibit anti-inflammatory effects in animal models.

Store the unopened lyophilized vial dry at 2-8°C for short-term storage, or at -20°C for long-term stability. Protect from light and moisture. Once reconstituted, refrigerate at 2-8°C and use within ~14 days. Avoid repeated freeze-thaw cycles, which can degrade peptide integrity.

Standard preclinical practice is to reconstitute the lyophilized blend with bacteriostatic water for injection (BAC). Add the diluent slowly down the side of the vial, then swirl gently - do not shake, as shaking can fragment peptide chains. Once dissolved, the solution should be clear. Document the final concentration based on the stated peptide mass per vial on the COA.

Published preclinical research includes rodent models of Achilles tendon transection, medial collateral ligament injury, crushed and transected skeletal muscle, gastrointestinal lesions, full-thickness dermal wounds, corneal abrasion, and myocardial infarction. In vitro work includes endothelial cell migration assays, fibroblast proliferation assays, and capillary tube-formation studies. Across these models, vascularization (BPC-157) and cytoskeletal/migratory (Tβ4) endpoints are common.

There are dozens of peer-reviewed preclinical publications for BPC-157 (primarily from the Sikiric group and collaborators) and a substantial Thymosin β4 literature spanning cardiac, dermal, corneal, and CNS injury models. However, neither compound is FDA-approved for human therapeutic use. All claims on this page refer to in vitro and animal-model findings. This material is sold strictly for preclinical research use only.